… patient deaths are preceded by a tumor recurrence. On an individual patient basis, in this
analysis, 80% of patients … , the vast majority of these patients with recurrent disease had died. In …

… The Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC) study, based
on individual patient data, compared locoregional treatment with locoregional treatment plus …

… Hence, although promising, more current data and prospective validation are needed before
we recommend the use of earlier end points such as 1-year DFS routinely in clinical trials. …

… End Points for Clinical Trials in HL For firstline therapy, we recommend that a PFS-based
end point be considered the primary end point in HL clinical trials. While not a surrogate for OS, …

… of TLR to each of the 4 potential surrogate end points (Table 4) and was examined for each
trial separately with individual patient data in both treatment groups combined. The highest c-…

… We analysed individual patients' data from 15 071 patients involved in 60 randomised clinical
… of surrogate end points in multiple randomized clinical trials with failure time end points. …

… The primary clinical end point (ie, true end point) of OS and the putative surrogate end point
of PFS were calculated by using individual patient data consistently across trials. OS was …

… patients with declining kidney function. The objective of this study was to explore kidney disease
end points in a large set of patients … Individual-patient data from 2 phase 2 and 11 phase …

… individual patients, the aim for clinicians should be to identify the preferences of each individual
patient … site-specific event rates and the available trial evidence to tailor therapy to that …

… We previously described the creation of the pooled individual-level patient-level data set. In
… May 15, 2007, and requested individual patient data from the investigators. Inclusion criteria …